Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria

被引:0
作者
Monika Russel-Szymczyk
Vasil Valov
Alexandra Savova
Manoela Manova
机构
[1] Novo Nordisk Pharma Sp. z o.o,Faculty of Pharmacy
[2] Novo Nordisk Pharma EAD,undefined
[3] Medical University Sofia,undefined
来源
BMC Endocrine Disorders | / 19卷
关键词
Cost-effectiveness; Diabetes; Hypoglycaemia; ICER; Insulin degludec; QALY;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 213 条
[1]  
Jonsson B(2013)Economic costs of diabetes in the U.S. in 2012 Diabetes Care 36 1033-1046
[2]  
Stratton IM(2002)Revealing the cost of type II diabetes in Europe Diabetologia. 45 S5-12
[3]  
Adler AI(2018)Economic costs of diabetes in the U.S. in 2017 Diabetes Care 41 917-928
[4]  
Neil HA(2000)Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ. 321 405-412
[5]  
Matthews DR(1993)The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group N Engl J Med 329 977-986
[6]  
Manley SE(2018)Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 41 2669-2701
[7]  
Cull CA(2011)Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials Diabetes Care 34 510-517
[8]  
Davies MJ(2018)Standards of medical care in diabetes-2018 Diabetes Care 41 S1-S153
[9]  
D'Alessio DA(2012)Optimization of insulin therapy in patients with type 2 diabetes mellitus: beyond basal insulin Diabet Med 29 e13-e20
[10]  
Fradkin J(2014)Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study Clin Endocrinol (Oxf) 80 47-56